- Health Canada DPD: FLUNARIZINE (AA PHARMA INC, DIN 02246082) · product monograph (PDF)
- Spain CIMA (Spanish): search for “flunarizina” (external search; text not reproduced)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Contraindications
- History of depression
- Parkinson disease or other extrapyramidal disorders
- Hypersensitivity
Dosing: Adult
- Migraine prophylaxis (adults under 65): 10 mg once daily in the evening; stop if no improvement after 3 months
Dosing: Altered kidney function
Flunarizine is highly protein-bound (over 99%), metabolized by the liver and excreted very slowly, with negligible urinary excretion; its terminal half-life is about 19 days. The Canadian product monograph does not address kidney impairment or dialysis. It has no US FDA label.
Kidney function measure: The product monograph does not address kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Migraine prophylaxis: 10 mg once daily in the evening (adults under 65); stop after 3 months if no response (PM).
- CrCl 30–59 mL/min
- The product monograph does not address kidney impairment. Renal excretion is negligible (under 0.2% in urine over 48 hours). Use with caution and specialist judgment.
- CrCl 15–29 mL/min
- The product monograph does not address kidney impairment. Renal excretion is negligible (under 0.2% in urine over 48 hours). Use with caution and specialist judgment.
- CrCl <15 mL/min (not on dialysis)
- The product monograph does not address kidney impairment. Renal excretion is negligible (under 0.2% in urine over 48 hours). Use with caution and specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated (over 99% protein-bound; removal unlikely).
- Monitoring Depression (contraindicated with a history of depression), extrapyramidal symptoms (higher risk in older adults), sedation, weight gain; stop at the first sign. Review at 3 months and closely beyond 6 months (PM). Caution in hepatic impairment (PM); safety above 65 years not established.
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: Health Canada product information (February 15, 2022). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established under 18 years (PM).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Capsule: 5 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Flunarizine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
FlumigFlunarizine Hydrochloride | 5 mg capsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Unison Laboratories Co., Ltd.Thailand | JustRight Healthcare Inc. | DR-XY31562 | Dec 18, 2028 | |
FlunizFlunarizine (as dihydrochloride) | 5 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-14967 | Feb 27, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Alcohol, hypnotics, tranquilizers | Avoid | Excessive sedation. | Avoid. |
| Antihypertensives | Adjust or monitor | Additive blood-pressure lowering. | Antihypertensive dose may need reduction. |
| Two or more enzyme-inducing antiepileptics; mephenytoin | Minor | Lower flunarizine levels. | Monitor response. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Somnolence, sedation or fatigue (about 20%)
- Weight gain or increased appetite (about 15%)
Serious
- Depression
- Extrapyramidal symptoms, parkinsonism
- Galactorrhea
Monitoring parameters
- Depression (contraindicated with a history of depression), extrapyramidal symptoms (higher risk in older adults), sedation, weight gain; stop at the first sign. Review at 3 months and closely beyond 6 months (PM). Caution in hepatic impairment (PM); safety above 65 years not established. Kidney
- Mood; extrapyramidal signs; review at 3 and 6 months
- Caution in hepatic impairment; safety over 65 years not established
Pharmacokinetics
Key PK parameters
| Time to peak | 2 to 4 hours |
|---|---|
| Half-life | About 19 days (terminal) |
| Volume of distribution | 43.2 L/kg (mean) |
| Protein binding | 99.1% (under 1% free) |
| Metabolism (CYP, transporters) | Hepatic N-oxidation and aromatic hydroxylation |
| Renal excretion kidney | Under 0.2% in urine over 48 hours |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Flunarizine (as hydrochloride) |
| PNF listing | Oral: 5 mg capsule |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Canada. Flunarizine capsules product monograph (AA Pharma) [Health Canada product information, February 15, 2022; no US FDA label]. https://pdf.hres.ca/dpd_pm/00065007.PDF
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- AA Pharma Inc. (2022). Flunarizine (flunarizine hydrochloride) capsules 5 mg [Product monograph; revised February 15, 2022]. Health Canada Drug Product Database. https://pdf.hres.ca/dpd_pm/00065007.PDF
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .